

Jeanny B Aragon-Ching

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5608796/publications.pdf>

Version: 2024-02-01

152
papers

4,257
citations

172207

29
h-index

118652

62
g-index

153
all docs

153
docs citations

153
times ranked

5952
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances with androgen deprivation therapy for prostate cancer. Expert Opinion on Pharmacotherapy, 2022, 23, 1015-1033.	0.9	10
2	Contemporary treatment and survival differences in patients with urothelial versus nonurothelial bladder and upper tract carcinomas: Analyses from the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2022, 40, 463-463.	0.8	1
3	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.. Journal of Clinical Oncology, 2022, 40, 487-487.	0.8	23
4	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. Nature Communications, 2022, 13, 1878.	5.8	3
5	Rapidly evolving first-line therapy using checkpoint inhibitors in metastatic renal cell cancer. Future Medicinal Chemistry, 2022, , .	1.1	0
6	The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer. Asian Journal of Andrology, 2021, 23, 1.	0.8	7
7	The emerging role of checkpoint inhibitors for rare genitourinary cancers. Nature Reviews Urology, 2021, 18, 133-134.	1.9	0
8	Plasmacytoid Variant of Urothelial Carcinoma: Poor Prognostic Variant with High Expression of CDH1 Mutation. Uro, 2021, 1, 23-29.	0.3	3
9	Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies. Oncoscience, 2021, 8, 40-45.	0.9	1
10	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.. Journal of Clinical Oncology, 2021, 39, 4520-4520.	0.8	8
11	Comparative analyses of survival differences in patients with urothelial versus non-urothelial upper tract carcinomas: Results from the National Cancer Database (NCDB).. Journal of Clinical Oncology, 2021, 39, e16582-e16582.	0.8	0
12	Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.. Journal of Clinical Oncology, 2021, 39, 5079-5079.	0.8	3
13	Protein kinase inhibitors for the treatment of prostate cancer. Expert Opinion on Pharmacotherapy, 2021, 22, 1889-1899.	0.9	8
14	Pembrolizumab use in bladder cancer: a tale of two trials. Nature Reviews Urology, 2021, 18, 577-578.	1.9	6
15	A Contemporary Review of Immune Checkpoint Inhibitors in Advanced Clear Cell Renal Cell Carcinoma. Vaccines, 2021, 9, 919.	2.1	9
16	MP41-13â€fAVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF CLINICAL AND GENOMIC SUBGROUPS FROM THE JAVELIN BLADDER 100 TRIAL. Journal of Urology, 2021, 206, .	0.2	0
17	PD40-11â€fCLINICAL ACTIVITY OF NIVOLUMAB IN ADVANCED HEREDITARY LEIOMYOMATOSIS AND RENAL CELL CANCER (HLRCC)-ASSOCIATED KIDNEY CANCER. Journal of Urology, 2021, 206, .	0.2	0
18	Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer. Clinical Medicine Insights: Oncology, 2021, 15, 117955492110449.	0.6	18

#	ARTICLE	IF	CITATIONS
19	Role of immunotherapy in bladder cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100296.	0.7	41
20	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	5.1	61
21	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 457-467.	0.8	7
22	Life under the CABOSUN: Cabozantinib improves quality-adjusted survival in comparison with sunitinib. <i>Cancer</i> , 2020, 126, 5210-5212.	2.0	1
23	Maintenance avelumab for metastatic urothelial cancer: a new standard of care. <i>Cancer Biology and Therapy</i> , 2020, 21, 1095-1096.	1.5	6
24	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020, 383, 1218-1230.	13.9	802
25	Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 483-490.	1.1	3
26	Characterization of Brain Metastases in Urothelial Cancers. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e679-e683.	0.9	1
27	The immunotherapy revolution in genitourinary malignancies. <i>Immunotherapy</i> , 2020, 12, 819-831.	1.0	10
28	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA1-LBA1.	0.8	64
29	Darolutamide for treatment of castration-resistant prostate cancer. <i>Drugs of Today</i> , 2020, 56, 185.	0.7	4
30	Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2020, 22, 76.	0.8	4
31	Pilot Study Assessing Distressors Affecting Patients with Cancer Using the Distress Thermometer Screening Tool. <i>Hematology & Medical Oncology</i> , 2020, 5, .	0.1	0
32	Carcinomas of the Renal Pelvis, Ureters, and Urinary Bladder Share a Carcinogenic Field as Revealed in Epidemiological Analysis of Tumor Registry Data. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 436-442.	0.9	7
33	Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?. <i>Journal of Clinical Oncology</i> , 2019, 37, 2296-2297.	0.8	2
34	Formidable Scenarios in Urothelial and Variant Cancers of the Urinary Tract. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 262-275.	1.8	3
35	The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2019, 13, 117955491983392.	0.6	30
36	Zoledronic acid for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 657-666.	0.9	23

#	ARTICLE	IF	CITATIONS
37	The Emerging Role of Combination Angiogenesis Inhibitors and Immune Checkpoint Inhibitors in the Treatment of Metastatic Renal Cell Cancer. <i>Kidney Cancer</i> , 2019, 3, 81-91.	0.2	1
38	Frontline immunotherapy treatment with nivolumab and ipilimumab in metastatic renal cell cancer: a new standard of care. <i>Cancer Biology and Therapy</i> , 2019, 20, 6-7.	1.5	7
39	Molecular profiling of aggressive variant urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 378-378.	0.8	3
40	Comparative analyses of trends and survival in patients with urothelial versus nonurothelial bladder carcinoma: National Cancer Database (NCDB) analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 402-402.	0.8	2
41	Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2019, 21, 107.	0.8	1
42	Carcinomas of the renal pelvis, ureters, and urinary bladder arise by similar carcinogenic pathways: A pathoepidemiological analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 403-403.	0.8	6
43	Non-urothelial bladder cancer: Genomic alterations and patient outcomes.. <i>Journal of Clinical Oncology</i> , 2019, 37, 399-399.	0.8	2
44	Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 85-89.	0.9	34
45	Multidisciplinary Management of Muscle-Invasive Bladder Cancer: Current Challenges and Future Directions. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 307-318.	1.8	35
46	Vitamin D in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 244.	0.8	59
47	Epithelioid Angiosarcoma of the Bladder: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1091-e1095.	0.9	8
48	Differences in survival among non-urothelial bladder cancers: Analyses of SEER 1988-2008.. <i>Journal of Clinical Oncology</i> , 2018, 36, 425-425.	0.8	4
49	The path forward in prostate cancer therapeutics. <i>Asian Journal of Andrology</i> , 2018, 20, 213.	0.8	3
50	Role of chemotherapy in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 221.	0.8	85
51	Molecular characterization of brain metastases in patients with metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 509-509.	0.8	0
52	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 1341-1367.	0.8	318
53	Challenges and advances in the diagnosis, biology, and treatment of urothelial upper tract and bladder carcinomas. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 462-464.	0.8	11
54	Mucinous Signet-Ring Urachal Carcinoma of the Bladder: Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e889-e891.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Targeted therapies in the treatment of urothelial cancers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 465-472.	0.8	13
56	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2266-2277.	6.3	153
57	New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 330-336.	1.8	5
58	Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. <i>Cancer Management and Research</i> , 2017, Volume 9, 299-306.	0.9	3
59	Promises and Pitfalls of Primary Local Treatment in Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 914-914.	0.8	2
60	Retrospective review of clear cell and non-clear cell renal carcinomas: Characteristics and course in the pre-TKI (tyrosine kinase inhibitor) and post-TKI era.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16052-e16052.	0.8	1
61	Treatment utilization patterns for prostate cancer (PCa): An analysis from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2017, 35, 99-99.	0.8	1
62	New Developments and Challenges in Rare Genitourinary Tumors: Non-Urothelial Bladder Cancers and Squamous Cell Cancers of the Penis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 330-336.	1.8	5
63	Survival outcomes for de novo versus primary progressive metastatic prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 258-258.	0.8	0
64	Survival outcomes and patterns of utilization of cytoreductive nephrectomy in the tyrosine kinase inhibitors (TKI)-era in metastatic clear cell renal cell carcinoma (ccRCC) and non-clear cell renal cell carcinoma (nccRCC): Analyses from the National Cancer Database (NCDB).. <i>Journal of Clinical Oncology</i> , 2017, 35, e16068-e16068.	0.8	0
65	Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHARTED. <i>Asian Journal of Andrology</i> , 2016, 18, 444.	0.8	0
66	Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10, 11.	0.6	27
67	Targeting Bone Metastases in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.Ss30751.	0.6	3
68	A multicentre, international, randomised, open-label phase 3 trial of avelumab + best supportive care (BSC) vs BSC alone as maintenance therapy after first-line platinum-based chemotherapy in patients with advanced urothelial cancer (JAVELIN bladder 100). <i>Annals of Oncology</i> , 2016, 27, vi292.	0.6	11
69	Key Difficulties Associated with Cancer Biology. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S41271.	0.6	0
70	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S34535.	0.6	34
71	Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises. <i>Future Oncology</i> , 2016, 12, 2049-2058.	1.1	8
72	The promising role of nivolumab in renal cell cancers. <i>Cancer Biology and Therapy</i> , 2016, 17, 123-124.	1.5	7

#	ARTICLE	IF	CITATIONS
73	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1500-1509.	0.8	72
74	A phase I/II trial of ketoconazole + calcitriol [1,25(OH)2D3] in castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5065-5065.	0.8	1
75	The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2016, 16, 1166-1171.	0.9	3
76	The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer. <i>Asian Journal of Andrology</i> , 2016, 18, 592.	0.8	2
77	Effects of PSA screening guidelines on trends of diagnosis and treatment for prostate cancer: Analysis from the National Cancer Data Base (NCDB).. <i>Journal of Clinical Oncology</i> , 2016, 34, 74-74.	0.8	0
78	Incidence and characterization of pure non-urothelial bladder and upper tract cancers: A 10-year review.. <i>Journal of Clinical Oncology</i> , 2016, 34, 414-414.	0.8	0
79	2508 Three-arm phase II randomized trial of docetaxel monotherapy or combined with ramucirumab or icrucumab in second-line locally advanced or metastatic urothelial carcinoma. <i>European Journal of Cancer</i> , 2015, 51, S476.	1.3	3
80	Radium-223 for the treatment of castration-resistant prostate cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 1103.	1.0	10
81	A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1059-1073.	1.9	7
82	Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e341-e345.	0.9	11
83	Drug therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2015, 11, 2395-2403.	1.1	1
84	Characterization of differences between prostate cancer (PCa) patients presenting as de novo versus primary progressive metastatic disease.. <i>Journal of Clinical Oncology</i> , 2015, 33, 285-285.	0.8	2
85	Pilot study assessing distressors affecting patients with cancer using the distress screening tool.. <i>Journal of Clinical Oncology</i> , 2015, 33, 68-68.	0.8	0
86	Advanced prostate cancer – patient survival and potential impact of enzalutamide and other emerging therapies. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 651.	0.9	6
87	Further analysis of PREVAIL: Enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2014, 16, 803.	0.8	2
88	Ipilimumab. <i>Cancer Biology and Therapy</i> , 2014, 15, 1299-1300.	1.5	5
89	Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Are We Asking the Right Questions?. <i>Journal of Clinical Oncology</i> , 2014, 32, 4169-4170.	0.8	4
90	Advances in systemic therapies for metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 2213-2226.	1.1	4

#	ARTICLE	IF	CITATIONS
91	Targeting the androgen receptor in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2014, 10, 329-332.	1.1	1
92	The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor. <i>Frontiers in Oncology</i> , 2014, 4, 295.	1.3	28
93	Circulating Tumor Cells. , 2014, 19, 229-233.		0
94	American Cancer Society prostate cancer survivorship care guidelines. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 225-249.	157.7	324
95	Phase II Study of Satraplatin and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Pharmacogenetic Assessment of Outcome and Toxicity. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 229-237.	0.9	23
96	Use of Denosumab for Renal Cell Carcinoma-Associated Malignant Hypercalcemia: A Case Report and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2013, 11, e24-e26.	0.9	6
97	Primary Diffuse Large B-Cell Lymphoma of the Ureter in a Patient With HIV: A Case Report and Review of Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 324-326.	0.2	8
98	Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide. <i>Clinical Medicine Insights: Oncology</i> , 2013, 7, CMO.S11670.	0.6	22
99	Bone-Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer: Evolving Paradigms. <i>Prostate Cancer</i> , 2013, 2013, 1-10.	0.4	33
100	Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?. <i>Future Oncology</i> , 2013, 9, 619-622.	1.1	2
101	The changing landscape in the treatment of metastatic castration-resistant prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2013, 5, 25-40.	1.4	40
102	Circulating tumor cells (CTCs) in biochemical recurrence (BR) of prostate cancer: Final results.. <i>Journal of Clinical Oncology</i> , 2013, 31, 179-179.	0.8	1
103	Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled. <i>Current Molecular Pharmacology</i> , 2013, 5, 382-391.	0.7	1
104	Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS metastases: the Road less Travelled. <i>Current Molecular Pharmacology</i> , 2013, , .	0.7	0
105	Enzalutamide (formerly MDV3100) as a new therapeutic option for men with metastatic castration-resistant prostate cancer. <i>Asian Journal of Andrology</i> , 2012, 14, 805-806.	0.8	5
106	Treatment of Adult Soft Tissue Sarcoma: Old Concepts, New Insights, and Potential for Drug Discovery. <i>Cancer Investigation</i> , 2012, 30, 300-308.	0.6	13
107	Complete Response to EPOCH in a Patient With HIV and Extracavitary Primary Effusion Lymphoma Involving the Colon: A Case Report and Review of Literature. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 144-147.	0.2	11
108	Hematuria in sickle cell trait: the importance of ruling out occult cancer. <i>Annals of Hematology</i> , 2012, 91, 137-138.	0.8	1

#	ARTICLE	IF	CITATIONS
109	Circulating tumor cells (CTCs) as a predictor of metastatic disease in patients with biochemical recurrence (BR) of prostate cancer with equivocal scan results.. Journal of Clinical Oncology, 2012, 30, 239-239.	0.8	0
110	Unravelling the role of denosumab in prostate cancer. Lancet, The, 2011, 377, 785-786.	6.3	17
111	Positron emission tomography findings in clinical mimics of lymphoma. Annals of the New York Academy of Sciences, 2011, 1228, 19-28.	1.8	8
112	Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine, 2011, 364, 579-580.	13.9	6
113	From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Review of Vaccines, 2011, 10, 743-753.	2.0	20
114	Implications for chemoprevention of prostate cancer with intake of cruciferous vegetables. Asian Journal of Andrology, 2011, 13, 357-358.	0.8	1
115	Editorial [Hot Topic: Multidrug Resistance: Genes, Polymorphisms, Biologic Effects, Reversal and Treatment in Cancer Chemotherapy (Guest Editor: Jeanny B. Aragon-Ching)]. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 582-582.	0.9	1
116	Mucosa-Associated Lymphoma Tissue of the Dura Presenting as Meningioma. Southern Medical Journal, 2010, 103, 950-952.	0.3	15
117	Angiogenesis Inhibition in Prostate Cancer: Current Uses and Future Promises. Journal of Oncology, 2010, 2010, 1-7.	0.6	27
118	New Pharmacotherapies in the Treatment of Advanced Prostate Cancer. Clinical Medicine Insights Urology, 2010, 4, CMU.S5075.	0.4	0
119	Active Surveillance for Prostate Cancer: Has the Time Finally Come?. Journal of Clinical Oncology, 2010, 28, e265-e266.	0.8	5
120	About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?. Annals of Oncology, 2010, 21, 183-184.	0.6	3
121	The use of 5-alpha-reductase inhibitors for the prevention of prostate cancer. Cancer Biology and Therapy, 2010, 10, 11-12.	1.5	1
122	Mechanisms of Drug Resistance to Vascular Endothelial Growth Factor (VEGF) Inhibitors. Anti-Cancer Agents in Medicinal Chemistry, 2010, 10, 593-600.	0.9	1
123	Novel androgen deprivation therapy (ADT) in the treatment of advanced prostate cancer. Drug Discovery Today: Therapeutic Strategies, 2010, 7, 31-35.	0.5	9
124	Investigational Angiogenesis Inhibitors. , 2010, , 225-232.		1
125	Angiogenesis inhibitors in prostate cancer therapy. Discovery Medicine, 2010, 10, 521-30.	0.5	13
126	Editorial [Hot topic: Prostate Cancer Therapy (Guest Editors: N. Sharifi and J.B. Aragon-Ching)]. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 1039-1039.	0.9	2

#	ARTICLE	IF	CITATIONS
127	Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 650-660.	1.0	52
128	Cardiovascular Disease With Androgen Deprivation: The (forgotten) Role of Testosterone. <i>Journal of Clinical Oncology</i> , 2009, 27, e261-e261.	0.8	1
129	Further analysis of the survival benefit of clodronate. <i>Cancer Biology and Therapy</i> , 2009, 8, 2219-2220.	1.5	3
130	Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2009, 9, 1040-1045.	0.9	2
131	Reply. <i>Clinical Cancer Research</i> , 2009, 15, 7749-7749.	3.2	0
132	Hand-Foot Skin Reaction Increases with Cumulative Sorafenib Dose and with Combination Anti-Vascular Endothelial Growth Factor Therapy. <i>Clinical Cancer Research</i> , 2009, 15, 1411-1416.	3.2	135
133	Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2009, 103, 1636-1640.	1.3	112
134	Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents. <i>Cancer Investigation</i> , 2009, 27, 221-226.	0.6	115
135	Anti-angiogenesis approach to genitourinary cancer treatment. <i>Update on Cancer Therapeutics</i> , 2009, 3, 182-188.	0.9	22
136	A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation. <i>Journal of Urology</i> , 2009, 181, 1104-1113.	0.2	41
137	VEGF Inhibitors and Prostate Cancer Therapy. <i>Current Molecular Pharmacology</i> , 2009, 2, 161-168.	0.7	59
138	Kinetics of Serum Androgen Normalization and Factors Associated With Testosterone Reserve After Limited Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. <i>Journal of Urology</i> , 2008, 180, 1432-1437.	0.2	36
139	ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel. <i>Clinical Cancer Research</i> , 2008, 14, 4543-4549.	3.2	127
140	A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 209-214.	3.2	174
141	Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel. <i>Clinical Cancer Research</i> , 2008, 14, 4200-4205.	3.2	204
142	Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab. <i>Acta Oncologica</i> , 2008, 47, 1600-1601.	0.8	24
143	Osteonecrosis of the Jaw and the Use of Antiangiogenic Agents: Just an Association?. <i>Oncologist</i> , 2008, 13, 1314-1314.	1.9	8
144	The Role of Angiogenesis Inhibitors in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2008, 14, 20-25.	1.0	31

#	ARTICLE	IF	CITATIONS
145	The Clinical Utility of Bevacizumab. , 2008, , 375-385.		2
146	Exploratory covariate analysis for phase II clinical trial of sorafenib (S) in metastatic castrate-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 2008, 26, 14690-14690.	0.8	0
147	CNS Metastasis: An Old Problem in a New Guise. Clinical Cancer Research, 2007, 13, 1644-1647.	3.2	89
148	Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Frontiers in Bioscience - Landmark, 2007, 12, 4957.	3.0	130
149	Lack of prognostic significance of prostate biopsies in metastatic androgen independent prostate cancer. BJU International, 2007, 100, 1245-1248.	1.3	0
150	Osteonecrosis of the jaw (ONJ) in androgen-independent prostate cancer (AIPC) patients receiving ATTP (bevacizumab, docetaxel, thalidomide, and prednisone). Journal of Clinical Oncology, 2007, 25, 19594-19594.	0.8	4
151	Thalidomide Analogues as Anticancer Drugs. Recent Patents on Anti-Cancer Drug Discovery, 2007, 2, 167-174.	0.8	69
152	Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?. Cancer Therapy, 2007, 5A, 151-160.	2.9	12